Who is the CEO of Bluemtec?

According to the DART company overview, Bluemtec's representative director is 김준석 (name as registered in Korean). The company was founded on 2015-03-26.

Where is Bluemtec listed?

Bluemtec trades on the Korea Exchange KOSDAQ market under the ticker 439580. Its fiscal year ends in December.

Does Bluemtec pay a dividend?

Bluemtec did not pay a cash dividend for fiscal 2025, according to its annual report.

Does Bluemtec have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: Dilution risk (rights offering or CB/BW/EB issue decided in the past 90 days); Revenue +30% (latest quarterly revenue up more than 30% year on year); Major holder adding (a 5%+ shareholder reported raising its stake (30 days)); Control change (change of largest shareholder, or a contract that would cause one (90 days)). These are factual flags, not investment advice.

Which companies are in the same industry as Bluemtec?

Under the Korean Standard Industrial Classification recorded on DART, Bluemtec is grouped with 36 other listed companies in wholesale trade. The most covered in Korean news over the past 30 days are Samsung C&T, Jindo and SK Gas.

Bluemtec KRX:439580KOSDAQ

블루엠텍 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h0

Articles, 7 days1

DART filings, 7 days5

Articles tracked17since Sep 11

In Q3 2026, Bluemtec reported revenue of ₩90.4bn, up 73.4% year on year, and operating profit of ₩1.1bn. Bluemtec (블루엠텍) appeared in 1 Korean news article and 5 DART filings over the past seven days. Coverage peaked on Nov 5 with 4 articles. The most common catalyst was earnings (5).

Filing signals Revenue +30% Major holder adding Control change Dilution risk Screener

Bluemtec quarterly results consolidated, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q3 2026	₩90.4bn	+73.4%	₩1.1bn margin 1.2%	₩937m
Q2 2026	₩55.0bn	+20.4%	₩182m margin 0.3%	₩2.0bn
Q1 2026	₩44.0bn	+28.9%	−₩743m margin −1.7%	₩2.6bn
Q4 2025 derived	₩53.9bn	+64.0%	−₩488m margin −0.9%	₩79m
Q3 2025	₩52.1bn	+10.6%	₩347m margin 0.7%	−₩487m
Q2 2025	₩45.7bn	+78.2%	−₩800m margin −1.8%	−₩2.5bn
Q1 2025	₩34.2bn	+23.7%	−₩1.0bn margin −3.0%	−₩1.6bn
Q4 2024 derived	₩32.9bn	-0.9%	−₩3.3bn margin −9.9%	−₩1.9bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Bluemtec top stories 2 weeks, by number of outlets

1
BlueEm Tech obesity drug and vaccine distributor Q3 sales surge 73 percent; swings to cumulative profit
2 outlets · 2 articlesFirst report Nov 5 13:07 조선비즈Earnings
2
BlueMTech Q3 provisional results up 75% year-over-year
1 outlets · 1 articlesFirst report Nov 5 11:54 베타뉴스Earnings
3
Blue M-Tech announces third-quarter preliminary results...sales increase 73.4%
1 outlets · 1 articlesFirst report Nov 5 17:00 메디포뉴스Earnings
4
Bluem Tech Q3 operating profit surges 212.4% year-on-year
1 outlets · 1 articlesFirst report Nov 10 13:21 물류신문Earnings
5
Blue M Tech announces largest shareholder change share acquisition transferee change
1 outlets · 1 articlesFirst report Nov 2 08:45 한스경제Stake / acquisition
6
Blue Em Tech decides 36 billion won CB after terminating trust contract...final cash of 10.93 billion won with single dilution of 32.88%
1 outlets · 1 articlesFirst report Nov 4 19:00 데일리연합

Latest Bluemtec news Korean headlines

Nov 1013:21

MajorBluem Tech Q3 operating profit surges 212.4% year-on-year
물류신문Earnings
Nov 517:00

MajorBlue M-Tech announces third-quarter preliminary results...sales increase 73.4%
메디포뉴스Earnings
Nov 513:07
MajorBlueEm Tech obesity drug and vaccine distributor Q3 sales surge 73 percent; swings to cumulative profit
조선비즈Earnings
1 more on this story · 1 outlets
- BlueEm Tech obesity drug and vaccine distributor Q3 sales surge 73 percent; swings to cumulative profit조선일보 · Nov 5 13:10
Nov 511:54

MajorBlueMTech Q3 provisional results up 75% year-over-year
베타뉴스Earnings
Nov 419:00

Blue Em Tech decides 36 billion won CB after terminating trust contract...final cash of 10.93 billion won with single dilution of 32.88%
데일리연합
Nov 208:45

Blue M Tech announces largest shareholder change share acquisition transferee change
한스경제Stake / acquisition
Oct 3112:04

Blue M Tech to change CB acquisition target with 36 billion won
비건뉴스
Oct 2010:59

Blue M Tech major shareholder exits at 23.1 billion won, remaining shareholders worry about stake dilution
한스경제
Oct 818:20

BlueemTech to issue 36 billion won convertible bonds, raise 31 billion won in operating funds
CBC뉴스
Oct 713:52

BlueemTech management rights sale near final contract, Korean Securities Finance due diligence complete
머니투데이Stake / acquisition
Oct 610:00

Yuan Medical to form strategic partnership with BlueemTech on NMN ETELLA, expand domestic market distribution
바이오타임즈
Sep 3008:36
Korea Kolmar to acquire BlueemTech, seeking synergies from AI and data-based distribution to HK Inoene
이데일리Kolmar Korea HK inno.N
1 more on this story · 1 outlets
- Korea Kolmar to acquire BlueemTech, seeking synergies from AI and data-based distribution to HK Inoene이데일리 · Sep 30 08:36
Sep 2905:52

BlueemTech, Kolmar after years of collaboration, considering management rights acquisition
약사공론Stake / acquisition
Sep 2408:38

Cellid, Blue M Tech stir with management control sale news; Inventera rises
이데일리Stake / acquisitionInventera Cellid
Sep 2214:44

MajorExclusiveBlueemTech to sell management rights at estimated 7 billion won
머니투데이Stake / acquisition

Articles per day 2 weeks

110

Company profile

CEO: 김준석
Industry: Wholesale trade
Founded: 2015-03-26
Fiscal year-end: December
Head office: 경기도 평택시
Website: bluemtec.com
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

Major shareholders latest 5%+ report per holder

Korea 5% stake disclosures

케이디비아이헬스케어밸류업40.60%
연제량22.71%
오라이언자산운용7.99%
에이원자산운용6.21%

Each holder's most recent 5% ownership report on DART; names as filed in Korean.

Same industry Wholesale trade

All in industry

Company	Latest quarter op. profit	Articles 30d
Samsung C&T	–	687
Jindo	–	141
SK Gas	₩148bn	59
SKNetworks	–	40
Gamsung	₩7.4bn	30
Daewon Media	₩8.1bn	25
Sonokong	–	14
Namsung	–	13

Compare Bluemtec side by side with these companies

Bluemtec DART filings

Nov 1316:14

Quarterly report (September 2026)
Other
Nov 1217:01

Reference materials for proxy voting solicitation
Other
Nov 1216:57

Notice of shareholders' meeting
Other
Nov 1216:53

Convocation of shareholders' meeting (extraordinary general meeting)
Other
Nov 1015:25

Report on large shareholdings in securities (general)
Ownership reports
Nov 617:09

Report on large shareholdings in securities (general)
Ownership reports
Nov 617:06

Report on large shareholdings in securities (general)
Ownership reports
Nov 616:02

Report on large shareholdings in securities (general)
Ownership reports
Nov 614:38

Securities issuance result (Voluntary filing) (Second series convertible bonds)
Other
Nov 416:49

Stock cancellation decision
Other
Nov 416:49

Operating results on consolidated financial statement basis (provisional) (fair disclosure)
Earnings & dividends
Nov 316:06

Trust contract termination result report
Other

Catalysts 2 weeks

Earnings5
Stakes & M&A1

Mentioned alongside 2 weeks

No co-mentioned companies yet.

Related themes

Obesity drugs2

Bluemtec FAQ

Who is the CEO of Bluemtec?: According to the DART company overview, Bluemtec's representative director is 김준석 (name as registered in Korean). The company was founded on 2015-03-26.
Where is Bluemtec listed?: Bluemtec trades on the Korea Exchange KOSDAQ market under the ticker 439580. Its fiscal year ends in December.
What were Bluemtec's latest quarterly results?: In Q3 2026, Bluemtec reported revenue of ₩90.4bn, up 73.4% year on year, and operating profit of ₩1.1bn. Figures come from reports filed on DART.
Does Bluemtec pay a dividend?: Bluemtec did not pay a cash dividend for fiscal 2025, according to its annual report.
Does Bluemtec have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: Dilution risk (rights offering or CB/BW/EB issue decided in the past 90 days); Revenue +30% (latest quarterly revenue up more than 30% year on year); Major holder adding (a 5%+ shareholder reported raising its stake (30 days)); Control change (change of largest shareholder, or a contract that would cause one (90 days)). These are factual flags, not investment advice.
Which companies are in the same industry as Bluemtec?: Under the Korean Standard Industrial Classification recorded on DART, Bluemtec is grouped with 36 other listed companies in wholesale trade. The most covered in Korean news over the past 30 days are Samsung C&T, Jindo and SK Gas.